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ARTICLE
Phosphoproteomics identifies a bimodal EPHA2
receptor switch that promotes embryonic
stem cell differentiation
Rosalia Fernandez-Alonso1, Francisco Bustos 1, Manon Budzyk1, Pankaj Kumar 2, Andreas O. Helbig3,
Jens Hukelmann4, Angus I. Lamond4, Fredrik Lanner 2, Houjiang Zhou1, Evangelia Petsalaki 5 &
Greg M. Findlay 1✉
Embryonic Stem Cell (ESC) differentiation requires complex cell signalling network dynamics,
although the key molecular events remain poorly understood. Here, we use phosphopro-
teomics to identify an FGF4-mediated phosphorylation switch centred upon the key Ephrin
receptor EPHA2 in differentiating ESCs. We show that EPHA2 maintains pluripotency and
restrains commitment by antagonising ERK1/2 signalling. Upon ESC differentiation, FGF4
utilises a bimodal strategy to disable EPHA2, which is accompanied by transcriptional
induction of EFN ligands. Mechanistically, FGF4-ERK1/2-RSK signalling inhibits EPHA2 via
Ser/Thr phosphorylation, whilst FGF4-ERK1/2 disrupts a core pluripotency transcriptional
circuit required for Epha2 gene expression. This system also operates in mouse and human
embryos, where EPHA receptors are enriched in pluripotent cells whilst surrounding lineage-
specified trophectoderm expresses EFNA ligands. Our data provide insight into function and
regulation of EPH-EFN signalling in ESCs, and suggest that segregated EPH-EFN expression
coordinates cell fate with compartmentalisation during early embryonic development.
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D ifferentiation of pluripotent embryonic stem cells (ESCs)into specialised cell types requires remodelling of tran-scriptional and protein networks coupled to an ability to
organise distinct cell populations1. This is driven by cellular
responses to extracellular stimuli and activation of intracellular
signalling networks. However, the key molecular changes that
drive differentiation remain obscure. A systems-level view of
developmental signalling is therefore required to comprehensively
map fundamental mechanisms that drive pluripotent exit and
acquisition of specialised cellular characteristics.
A critical signal driving differentiation of pluripotent cells is
fibroblast growth factor 4 (FGF4)2–6. FGF4 acts via multiple
signalling pathways, including ERK1/2, PI3K–AKT and PLCγ,
and plays an overarching role in specification and organisation
of early embryonic cell types7,8. Whilst FGF4 signalling pro-
foundly modifies gene expression and cellular behaviour to
promote differentiation9,10, the molecular mechanisms by which
the FGF4 network operates to drive differentiation remain
poorly understood.
In this paper, we employ phosphoproteomic profiling to identify
phosphorylation events by which FGF4 promotes exit from plur-
ipotency towards differentiation. We identify the EPHA2 receptor
tyrosine kinase as a critical target of the FGF4 signalling network in
ESCs. EPH receptors engage transmembrane Ephrin ligands
(EFNs)11 to drive segregation of EPH- and EFN- expressing cell
populations12, and demarcation of distinct cellular compart-
ments13. By exploring the function of EPH–EFN signalling in
pluripotent cells, we show that EPHA2 is the primary mediator of
EFN ligand responses in ESCs. Furthermore, activation of EPHA2
by EFNA1 supports pluripotency gene expression, and suppresses
commitment by restraining ERK1/2 activation. During ESC dif-
ferentiation, FGF4 signalling functionally disables EPHA2, which is
accompanied by transcriptional induction of EFN ligands. Inhibi-
tion of EPHA2 occurs via a dual mechanism: FGF4–ERK1/2 sig-
nalling to ribosomal S6 kinase (RSK/RPS6K) drives inhibitory
serine/threonine (S/T) phosphorylation of EPHA2, which blunts
the response to EFN ligand. In parallel, FGF4–ERK1/2 extinguishes
the pluripotency gene regulatory network to suppress Epha2
expression and inactivate EPH–EFN signalling in differentiating
ESCs. Our data thereby demonstrate a role for EPHA2 in plur-
ipotency maintenance, and identify key transcriptional and post-
translational mechanisms by which FGF4 signalling inhibits
EPHA2 to reinforce the transition from pluripotency towards
differentiation. Importantly, A-type EPH receptors are expressed in
the pluripotent compartment of both human and mouse embryos,
whilst the first specified lineage, trophectoderm, is enriched for
Efna1/EFNA1, suggesting that segregated expression of A-type
EPH receptors and EFN ligands plays a role in pluripotency
maintenance during early embryonic development.
Results
EPHA2 is serine phosphorylated upon ESC differentiation. In
order to comprehensively map potential mechanisms by which
phosphorylation controls ESC differentiation, we conducted a
phosphoproteomic survey of mouse ESC (mESC) signalling
responses to the key differentiation factor FGF4 (Fig. 1a). To this
end, we employ Fgf4−/− mESCs, which fail to activate FGF-
dependent signalling pathways and transcription required for
differentiation4, and therefore remain pluripotent14. Importantly,
providing Fgf4−/− mESCs with recombinant FGF4 restores sig-
nalling (Supplementary Fig. 1A) and differentiation responses4,14.
We employed this inducible system to screen for FGF4-
dependent phosphorylation sites following acute FGF4 stimulation
using mass-spectrometry (MS)-based phosphoproteomic profiling.
Although FGF4-dependent transcriptional responses require several
hours, maximal activation of key downstream signalling pathways,
such as ERK1/2 MAP kinase, occurs within minutes (Supplemen-
tary Fig. 1A)14. This suggests that proteins relevant for FGF4-
dependent differentiation are likely to be phosphorylated within
this time frame. Thus, control Fgf4−/−mESCs, or those stimulated
with FGF4 for 5 or 20min, were used to generate tryptic peptides.
Phosphopeptides were enriched, labelled and fractionated using
basic C18 reverse phase, and subjected to tandem MS (LC–MS/
MS) (Fig. 1b). This analysis quantified 19,846 phosphopeptides,
including 12,528 unique phosphosites on 3260 unique proteins.
Of these, ~56% have not been previously identified (5404 were
previously reported in PhosphositePlus15). The abundance of 2399
phosphopeptides is significantly altered at one or both time points
of FGF4 stimulation (>2-fold change). This cohort includes
known targets of the FGF4 pathway, including tyrosine phos-
phorylation of the scaffolding protein GAB1, and key components
of the ERK1/2 MAP kinase pathway downstream of FGF4, such
as SOS1, RAF1 or RPS6KA3 (Fig. 1c, d). Furthermore, this
dataset greatly expands our understanding of the FGF signalling
network in ESCs, when compared with previous large-scale
phosphoproteomics datasets of FGF stimulation in ESCs16,17
(Supplementary Fig. 1B).
As a means to pinpoint mechanisms by which FGF4 modulates
intracellular signalling during differentiation, we focussed on
the protein kinase superfamily. We find that FGF4 regulates
phosphorylation of a significant panel of protein kinases,
including pluripotency regulators RAF1, RPS6KA318 and poorly
studied members of the protein kinase superfamily (Fig. 1e).
Strikingly, EPHA2, a member of the Ephrin (EFN) receptor
tyrosine kinase family, is phosphorylated at S898 in response to
FGF4 stimulation (Fig. 1e). We confirm that this site is robustly
phosphorylated over a time course of FGF4 stimulation using an
EPHA2 S898 phosphospecific antibody (Fig. 1f), suggesting that
EPHA2 is a bona fide target of FGF4 signalling during mESC
differentiation.
EPHA2 is the most abundant receptor kinase in mESCs.
EPHA2 is a member of the large EPH receptor tyrosine kinase
family11, which prompted us to examine the expression profile of
EPH receptor family members in mESCs. Quantitative total cell
proteomics of around 10,000 proteins19 reveals that EPHA2 is the
major EPH receptor family member and the most abundant
receptor kinase in mESCs (Fig. 2a). mESCs also express EPHA4,
EPHB4, EPHB2 and EPHB3 at lower levels (Fig. 2a and Sup-
plementary Fig. 2A), consistent with cell surface proteomics from
mESCs and the early embryo20. Quantitative real-time poly-
merase chain reaction (qRT-PCR) analysis of members of the
mammalian EPH receptor family (EPHA1–8, EPHB1–4 and
EPHB6) confirms that Epha2, Epha4, Ephb2, Ephb3 and Ephb4
are expressed at the mRNA level in mESCs, along with Epha1 and
Epha7 (Supplementary Fig. 2B). However, our data suggest that
EPHA2 is the major EPH receptor expressed in mESCs, and may
therefore play a key role in driving EPH–EFN signalling in these
cells.
EPHA2 is an essential mediator of EFN signalling in mESCs. In
order to test the prediction that EPHA2 mediates EFN signalling
responses in mESCs, we developed an unbiased functional assay
to identify EPH receptor family members that engage EFN ligand
in cell extracts. This approach employs EFNA1 and B1 as
representatives of the EFNA and EFNB classes, which possess the
capacity to promiscuously engage EPHA and EPHB family
members, respectively21. EPH family members captured using
recombinant EFNA1 and B1 from mESC lysates were detected
and quantified using affinity purification MS (Fig. 2b). Proof of
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concept for this method was established by immunoblotting for
EPHA2, which is effectively captured by EFN pulldown (Fig. 2c).
Coomassie staining of EFNA1–B1 pulldowns confirms the cap-
ture of EFNA1 and B1, and reveals further specific bands in the
75–130-kDa molecular weight range (Fig. 2d). MS analysis of
these samples primarily identified EPHA2 associated specifically
with EFNA1, with few peptides identified from other EPH family
members (Fig. 2e). Therefore, although mESCs express several
EPH receptor family members, EPHA2 is the major family
member that engages EFN ligands.
To test the hypothesis that EPHA2 is a key regulator of EFN
signalling in mESCs, we generated Epha2−/− mESCs using
CRISPR/Cas9, and examined tyrosine-phosphorylated proteins
that interact with EFNA1–B1 following stimulation of mESCs.
EFNA1–B1 captures a single tyrosine-phosphorylated protein of
~100 kDa in Epha2+/+ mESCs (Fig. 2f). However, this is lost in
Epha2−/− mESCs (Fig. 2f), indicating that specific disruption of
EPHA2 expression abolishes the phosphotyrosine response to
EFNA1–B1 stimulation. These data suggest that EPHA2 is the
major receptor that mediates EFN signalling responses in mESCs.
However, we observe a moderate increase of Epha1 expression in
three Epha2−/− mESCs clonal cell lines (Supplementary Fig. 2C),
suggesting that compensatory upregulation22,23 in early embryo-
nic cells may mask embryonic Epha2−/− phenotypes.
EPHA2 activation by EFNA1 occurs in trans in mESCs.
Although EPHA2 can be activated by EFNA1-recombinant ligand
in mESCs (Fig. 2f), physiological EPH receptor activation occurs via
cell surface-expressed EFNs. Therefore, we set out to determine
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how EPHA2 is activated in mESCs. Interestingly, EPHA2 is
tyrosine phosphorylated in mESCs under standard leukaemia-
inhibitory factor (LIF) and foetal bovine serum (FBS) culture
conditions (Fig. 2g), which may be attributable to expression of
A-type EFN ligands such as EFNA1 in mESCs. Indeed, EFNA1-
expressing Epha2−/− mESCs robustly stimulate EPHA2 acti-
vation in Epha2+/+ mESCs following short-term co-culture
(Fig. 2h), indicating that EFNA1 drives EPHA2 activation in
trans. This is consistent with previous data reporting that trans
interactions between EPH receptors and EFN ligands activate
signalling, whilst cis interactions are inhibitory24–26.
EPH–EFN signalling supports pluripotency factor expression.
As EPH–EFN signalling is active in cultured mESCs, we next
sought to determine the function of this pathway in these cells.
To this end, we tested whether EPH–EFN signalling plays a role
in regulation of mESC pluripotency and/or differentiation. We
generated multiple Epha2−/− mESC clones and an isogenic
Epha2−/− mESC clone in which EPHA2 expression is stably
reintroduced at endogenous levels. Firstly, we used these mESC
lines to investigate the role of EPHA2 in controlling expression
of pluripotency gene regulatory network components. When
cultured in LIF/FBS conditions, Epha2−/− mESCs express
similar levels of pluripotency factors such as NANOG, KLF4
and OCT4, and the differentiation marker DNMT3B (Supple-
mentary Fig. 3A). However, following mESC differentiation
initiated by 48 h of LIF withdrawal, Epha2−/− mESCs display
reduced KLF4 and increased DNMT3B expression, when
compared with control Epha2+/+ mESCs (Fig. 3a). This effect
is rescued by EPHA2 expression in Epha2−/− mESCs (Fig. 3a).
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Thus, whilst EPHA2 is not required for pluripotency under
standard mESC culture conditions, EPHA2 supports expres-
sion of a subset of pluripotency genes upon LIF withdrawal.
Importantly, EPHA2 signalling has no effect on mESC pro-
liferation (Supplementary Fig. 3B, C).
EPH–EFN signalling restricts commitment to differentiation.
In order to directly determine whether EPHA2 restrains exit from
pluripotency, we performed commitment assays on mESCs cul-
tured in 2i media27. Epha2+/+ or Epha2−/− mESCs were differ-
entiated in N2B27 medium for 4 days, then replated in 2i medium
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and colonies assessed for alkaline phosphatase activity. As
expected, most cells commit to differentiation during N2B27
culture (Supplementary Fig. 3D). However, the number of alka-
line phosphatase-positive colonies recovered from Epha2+/+ was
significantly higher than that from Epha2−/− mESCs (Fig. 3b),
indicating that EPHA2 suppresses mESC commitment to
differentiation.
We also investigated the impact of activating EPH–EFN
signalling on mESC pluripotency maintenance. To this end, we
generated mESCs stably expressing the EFN ligand EFNA1, in
either an Epha2+/+ or Epha2−/− background. EFNA1-expressing
Epha2+/+ mESCs display an increase in EPHA2 tyrosine
phosphorylation, which correlates with elevated expression of
pluripotency markers NANOG and KLF4 (Fig. 3c). However,
expression of EFNA1 in Epha2−/− cells does not alter NANOG
and KLF4 expression (Fig. 3c), indicating that this effect occurs via
EPHA2 activation. In a similar vein, EFNA1-expressing Epha2+/+
mESCs show strong alkaline phosphatase staining and rounded
colony morphology following mESC commitment assay, in
contrast to EFNA1-expressing Epha2−/− mESCs (Supplementary
Fig. 3E). Taken together, our data indicate that EPHA2 activation
by EFNA1 supports key mESC morphological and transcriptional
characteristics, thereby uncovering a function for EPH–EFN
signalling in mESC pluripotency.
EPHA2 suppresses expression of differentiation markers. As
our data suggest that EPHA2 may function to restrict mESC dif-
ferentiation, we investigated the effects of EPHA2 in an embryoid
body (EB) differentiation model, which mimics elements of early
embryonic development. EB aggregation effectively promotes
multi-lineage differentiation, including Fgf5+ epiblast, and Bra-
chyury+, Mixl+ mesendoderm and Cer1+ endoderm (Fig. 3d).
This is accompanied by a concomitant decrease in expression of
pluripotency markers Nanog, Klf4 and Oct4, and induction of the
differentiation marker Dnmt3b (Supplementary Fig. 3F). Strik-
ingly, Epha2−/− mESCs display augmented expression of Fgf5,
Brachyury, Mixl and to a lesser extent Cer1 following EB differ-
entiation, which is restored by EPHA2 re-expression in Epha2−/−
EBs (Fig. 3d), consistent with a role for EPHA2 in suppressing
mESC differentiation.
We also explored the function of EPHA2 in controlling
pluripotency and differentiation when mESCs are maintained in
basal media containing the MEK1/2 inhibitor PD0325901 and
GSK3 inhibitor CHIR99021 (2i) to promote ‘ground state' naive
pluripotency prior to differentiation in N2B27 media. Again,
decay of pluripotency factors Nanog, Klf4 and Oct4 is not
significantly altered in Epha2−/− mESCs, although expression of
the early differentiation factor Dnmt3b is elevated in these cells
(Supplementary Fig. 3G). Epha2−/− mESCs also display sig-
nificantly elevated expression of the neural-specific markers Sox1
and Nestin following N2B27 differentiation (Supplementary
Fig. 3G). Expression of the axonal transport factor Kif1a shows
an upward trend, although this is not statistically significant
(Supplementary Fig. 3G). We also assessed expression of the
mesendoderm marker Brachyury in the 2i/N2B27 differentiation
system. However, Brachyury levels are high in 2i media due to
transcriptional activation observed upon Wnt pathway activation/
GSK3 inhibition (Supplementary Fig. 3G). Nevertheless, data
from the mESC commitment assay (Fig. 3b) and EB differentia-
tion system (Fig. 3d) indicate that EPHA2 restricts mESC
differentiation in distinct models, consistent with a general role of
EPHA2 in regulating commitment to differentiation. However,
further experiments are required to definitively elucidate the
function of EPHA2 in lineage specification.
EPHA2 activation antagonises ERK1/2 signalling in mESCs.
Our findings prompted us to determine the mechanism by which
EPHA2 supports mESC pluripotency and restricts commitment.
As the LIF–JAK–STAT3 and FGF4–ERK1/2 signalling pathways
play key roles in mESC pluripotency and differentiation,
respectively, we hypothesised that EPHA2 activation modulates
signalling via one or both of these pathways. Stimulation of
mESCs with clustered recombinant EFNA1 activates EPHA2, as
measured by EPHA2 tyrosine phosphorylation (Fig. 3e). Intri-
guingly, EPHA2 activation specifically suppresses ERK1/2 acti-
vation without affecting signalling via the LIF–JAK–STAT3
pathway (Fig. 3e). This is consistent with a previously described
role for EPHA2 in inhibiting ERK1/2 activation in other cellular
systems28,29, and suggests that EPHA2 restrains differentiation
via specific inhibition of ERK1/2.
Next, we investigated the proposed interaction between
EFN–EPH and ERK1/2 signalling pathways. FGF4–ERK1/2 inhibi-
tion promotes pluripotency gene expression even in Epha2−/−
mESCs, reversing the effects of Epha2 gene knockout on DNMT3B
and KLF4 expression (Supplementary Fig. 3H). We have shown
previously that addition of exogenous FGF4 to Fgf4−/− mESCs
elevates DNMT3B and suppresses KLF4 expression14, thereby
phenocopying Epha2 gene knockout. Furthermore, similar to
FGF4–ERK1/2 inhibition, EPHA2 activation drives expression of
NANOG (Fig. 3c), reinforcing the functional interaction between
Fig. 3 EFNA1-activated EPHA2 supports mESC pluripotency and restricts commitment to differentiation by suppressing ERK1/2 signalling. a Epha2+/+,
Epha2−/− or Epha2−/− mESCs (clone C4) stably expressing EPHA2 were cultured in the absence of LIF for 48 h. EPHA2, KLF4, DNMT3B, NANOG and
OCT4 levels were determined by immunoblotting. b Epha2+/+ or Epha2−/− (clone C4) mESCs were maintained in 2i or differentiated in N2B27 media for 72
or 96 h, respectively, whereupon 10% of cells were replated in 2i. Total alkaline phosphatase staining is represented relative to Epha2+/+ mESCs. The total
number of alkaline phosphatase-positive colonies for Epha2+/+ and Epha2−/− mESCs is shown, and also represented relative to Epha2+/+ mESCs. Data show
mean ± SEM (n= 3); statistical significance was determined using unpaired two-sided Student’s t test comparing Epha2−/− with the Epha2+/+ control
(****P < 0.0001, **P=0.0016). c Epha2+/+ or Epha2−/− (clone C4) mESCs stably expressing EFNA1, along with the respective parental controls, were grown
in LIF/FBS, and KLF4, NANOG, EPHA2, EFNA1 and ERK1/2 levels determined by immunoblotting, or EPHA2 immunoprecipitated and pTyr and EPHA2 levels
determined by immunoblotting. d Epha2+/+, Epha2−/− or Epha2−/− mESCs stably expressing EPHA2 were differentiated as embryoid bodies for 10 days, and
the levels of Fgf5, Brachyury, Mixl and Cer1 mRNA determined by qRT-PCR. Box-and-whisker plots show median, first and third quartiles, and maximum
and minimum values. The results shown are for technical replicates from two independent experiments, including three Epha2−/− clones (n= 3); statistical
significance at day 4 was determined using unpaired two-sided Student’s t test comparing each group with the Epha2+/+ control (ns= not significant,
*P= 0.0252, **P= 0.0045, ***P < 0.0001). e Epha2+/+ mESCs cultured in LIF/FBS were stimulated with 1 μg/ml clustered EFNA1 for the indicated times.
ppERK1/2, total ERK1/2, STAT3 pY705 and total STAT3 levels were determined by immunoblotting. EPHA2 was immunoprecipitated, and pTyr and EPHA2
levels determined by immunoblotting. ppERK1/2 signal was quantified; data show mean ± SD (n= 3); statistical significance was determined using one-sample
two-sided t test comparing each group with control, theoretical mean= 1 (ns= not significant, 5 min; *P= 0.0467, 30min; ***P= 0.0005, 45min; **P=
0.0014, 60min; **P=0.0018). f Epha2+/+ mESCs cultured in LIF/FBS were stimulated with 1 μg/ml clustered EFNA1 for the indicated times. SHP2 was
immunoprecipitated, and SHP2 and EPHA2 levels detected by immunoblotting. Source data are provided as a Source Data file.
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EFN–EPH and ERK1/2 signalling in regulating pluripotency gene
expression. In summary, our data indicate that EFN–EPH and
FGF4–ERK1/2 have broadly opposing functions in regulating
expression of pluripotency gene network components. However,
it should be noted that NANOG expression is not significantly
altered in Epha2−/− mESCs (Fig. 3a).
To provide further mechanistic insight, we sought to
determine how EPHA2 intersects with the ERK1/2 pathway.
SHP2/PTPN11 is a protein tyrosine phosphatase that provides a
key scaffold14 to promote ERK1/2 activation and ESC
differentiation30–33. As EPHA2 has been shown to interact with
SHP234, we tested whether EPHA2 engages SHP2 in mESCs.
Indeed, EFNA1 stimulation drives recruitment of SHP2 to
EPHA2 (Fig. 3f), suggesting that EPHA2 activation inhibits
ERK1/2, either by sequestering the key scaffold SHP2, or by
recruiting SHP2 to dephosphorylate key phosphotyrosine sites
that are required for ERK1/2 activation.
FGF4–RSK signalling promotes EPHA2 S/T phosphorylation.
As demonstrated, FGF4-dependent differentiation signalling
promotes EPHA2 S898 phosphorylation (Figs. 1f, 4a). This
prompted us to investigate the regulation and function of EPHA2
S898 phosphorylation in mESCs. Previous studies have impli-
cated several kinases in phosphorylation of the EPHA2 S898
motif, including the AGC family kinase AKT, p90 ribosomal S6
kinase (RSK/RPS6K) and PKA35–37. FGF4-dependent EPHA2
S898 phosphorylation in mESCs is blocked by the FGFR inhibitor
AZD4547 and MEK1/2 inhibitor PD0325901 (Fig. 4b), confirm-
ing a key role for the FGF4–ERK1/2 MAP kinase pathway. As
RSK is phosphorylated and activated by ERK1/238, we hypothe-
sised that RSK is the EPHA2 S898 kinase in mESCs. Indeed,
structurally distinct RSK inhibitors BI-D1870 and SB747651A
block FGF4-dependent EPHA2 S898 phosphorylation (Fig. 4b).
Importantly, these inhibitors do not consistently inhibit AKT
activation (Fig. 4b), whilst EPHA2 S898 phosphorylation is
insensitive to PI3K inhibitors Wortmannin and LY294002
(Fig. 4b). Therefore, our data define the FGF4–ERK1/2–RSK
pathway, rather than PI3K–AKT, as the major driver of EPHA2
S898 phosphorylation in response to FGF4 in mESCs.
S898 lies in the intracellular region of EPHA2 proximal to the
kinase domain. Within this motif lie four further S/T residues
previously identified by MS analysis (Fig. 4a, www.phosphositeplus.
org)37. We therefore examined phosphorylation of this motif in
FGF4-stimulated mESCs by MS. Analysis of endogenous EPHA2
immunoprecipitated from Fgf4−/− mESCs stimulated with FGF4
and EFNA1 reveals a tryptic peptide containing the S898 motif.
This motif is phosphorylated on at least three S/T residues
(Supplementary Table 1), although it was not possible to discern the
exact positions by this method. Nevertheless, these data suggest
extensive phosphorylation of the EPHA2 S898 motif in mESCs.
EPHA2 S/T phosphorylation inhibits activation. We then
explored the role of S898 motif phosphorylation in EPHA2 reg-
ulation. To this end, we exploited Epha2−/− mESCs reconstituted
with approximately endogenous EPHA2 expression levels to
examine EPHA2 activation under conditions where signalling is
acutely responsive to EFNA1 ligand stimulation (Supplementary
Fig. 4A). Wild-type EPHA2 is efficiently activated by EFNA1
ligand, as measured by tyrosine phosphorylation (Fig. 4c and
Supplementary Fig. 4B). However, phosphomimetic mutation of
the five S/T sites within the S898 motif (5E) significantly inhibits
EPHA2 activation by clustered EFNA1 (Fig. 4c and Supplementary
Fig. 4B). These data suggest that multisite S/T phosphorylation at
the S898 motif disrupts ligand-induced EPHA2 tyrosine kinase
activation.
In order to test this directly, we generated knock-in (KI) mESC
lines expressing wild-type EPHA2 (WT KI) or a non-
phosphorylatable mutant at the five S/T sites within the S898
motif (5A KI). Consistent with the inhibitory role of S898 motif
phosphorylation on EPHA2 activation, EPHA2 5A is more active
than wild-type EPHA2 (Fig. 4d). This result prompted us to
examine the phenotype of EPHA2 5A KI mESCs. Strikingly,
EPHA2 5A KI mESC colonies display a rounded morphology
(Fig 4e), characteristic of ground-state pluripotency39, which also
resembles the morphology of mESCs in which EPHA2 is
activated by EFNA1 (Supplementary Fig. 3E). Furthermore,
EPHA2 5A KI mESCs show elevated expression of pluripotency
markers NANOG and OCT4, which is accompanied by reduced
expression of the differentiation marker DNMT3B (Fig. 4f).
These data support the notion that S898 motif phosphorylation
inhibits EPHA2 activation, and suppresses key morphological
and transcriptional characteristics associated with pluripotent
mESCs.
FGF4 signalling suppresses EPHA2 during differentiation.
Given that FGF4 signalling dynamically remodels gene expression
during mESC differentiation9, we next investigated whether FGF4
might also control expression of EPH receptor genes. We
employed EB aggregation as an FGF4–ERK1/2-dependent dif-
ferentiation model (Supplementary Fig. 4C) to explore EPH–EFN
gene expression dynamics. Epha2 and Epha4 mRNAs are sub-
stantially downregulated by day 6 (Fig. 4g; Supplementary
Fig. 4D), which closely mirrors pluripotency factor suppression
(Supplementary Fig. 3F). In contrast, EFN expression increases
upon mESC differentiation (Fig. 4h), suggesting that FGF4 sup-
presses EPH receptor gene expression whilst driving increased
expression of EFN ligands. Indeed, differentiation of Fgf4−/−
mESCs in response to recombinant FGF4 similarly suppresses
EPHA2 expression (Supplementary Fig. 4E).
We also investigated whether EPH and EFN gene expression is
responsive to FGF4 signalling during differentiation in the 2i
mESC model39. Indeed, removal of 2i activates FGF4–ERK1/
2 signalling, leading to similar suppression of Epha2 mRNA
(Fig. 4i) and EPHA2 protein (Supplementary Fig. 4F), with a
corresponding increase in Efna1 mRNA (Fig. 4j). EPHA2 sup-
pression is reversed by treatment of differentiating 2i mESCs with
FGFR inhibitor AZD4547 or MEK1/2 inhibitor PD0325901, but
not with the RSK inhibitor BI-D1870 or the PI3K inhibitor
Wortmannin (Supplementary Fig. 4G). These results provide
multiple lines of evidence that FGF4–ERK1/2 activity inhibits
Epha2 gene transcription. However, unlike inhibitory EPHA2
S898 phosphorylation, this appears to be regulated independent
of RSK kinase activity.
The pluripotency gene network controls Epha2 expression. Our
results thus far suggest a close correlation between expression of
EPHA2 and pluripotency factors (Fig. 4g, i, Supplementary
Fig. 4E–G). We therefore tested whether the master pluripotency
transcription factor OCT440 governs EPHA2 expression.
OCT4 siRNA knockdown specifically suppresses EPHA2 expres-
sion (Fig. 5a), in contrast to knockdown of the SOX2 pluripotency
transcription factor (Fig. 5a), which shares many targets with
OCT441, and has a similar impact on NANOG/DNMT3B plur-
ipotency signature (Supplementary Fig. 5A). Similarly, NANOG
knockdown does not impact on EPHA2 expression (Supplemen-
tary Fig. 5B), and suppression of EPHA2 expression by the BRD4
inhibitor JQ1 correlates with loss of OCT4, but not NANOG
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(Supplementary Fig. 5C). Thus, our results support a major role
for OCT4 in regulating EPHA2 expression. However, it has been
previously reported that loss of SOX2 leads to reduced Oct4
expression42, and we cannot rule out the possibility that residual
SOX2 and/or NANOG expression is sufficient to sustain expres-
sion of EPHA2.
In principle, EPHA2 suppression upon OCT4 depletion could
occur as an indirect consequence of mESC differentiation. To test
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Fig. 4 FGF4–ERK1/2 signalling inhibits EPHA2 activation and rewires EPH–EFN expression. a Diagram of potential phosphorylation sites within the
EPHA2 S898 motif. Mass spectrometry analysis detects phosphorylation of at least three sites in EPHA2 immunoprecipitated from FGF4-stimulated
Fgf4−/− mESCs (see Supplementary Table 1). b Fgf4−/− mESCs were treated with 10 μM of the indicated inhibitors for 1 h, and stimulated with FGF4 for
10min. EPHA2 pS898, EPHA2 and AKT pS473 levels were determined by immunoblotting. c Epha2−/− mESCs were transfected with either wild type or 5E
EPHA2 constructs, and stimulated with 1 μg/ml clustered EFNA1 for 15 min. EPHA2 was immunoprecipitated, and pTyr and EPHA2 levels determined by
immunoblotting and quantified. Data show mean ± SD (n= 4). d EPHA2 was immunoprecipitated from EPHA2 WT knock-in (KI) or 5A KI cell lines and
pTyr and EPHA2 levels determined by immunoblotting (upper panel). Relative pTyr/EPHA2 signal was quantified (lower panel). Data show mean ± SD
(n= 4). e Phase-contrast images of EPHA2 WT KI or 5A KI mESC lines; scale bar= 100 µM. f EPHA2 WT KI or 5A KI cell lines were cultured in LIF/FBS
medium for 48 h, and KLF4, NANOG, DNMT3B, OCT4 ppERK1/2 and ERK1/2 levels determined by immunoblotting. g Epha2+/+ mESCs were
differentiated as embryoid bodies for 10 days, and EPH receptor expression determined by qRT-PCR at the indicated time points. Box-and-whisker plots
show median, first and third quartiles, and maximum and minimum values of four technical replicates (n= 4). h Epha2+/+ mESCs were differentiated as
embryoid bodies for 10 days, and EFN ligand expression determined by qRT-PCR at the indicated time points. Box-and-whisker plots show median, first and
third quartiles, and maximum and minimum values of four technical replicates (n= 4). Epha2 (i) and Efna1 (j) mRNA expression in 2i mESCs undergoing
differentiation in N2B27 was determined by qRT-PCR analysis at the indicated time points. Box-and-whisker plots show median, first and third quartiles,
and maximum and minimum values of two technical and three biological replicates (n= 3). Source data are provided as a Source Data file.
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this possibility, we performed acute (24 h) depletion of OCT4 by
siRNA, which suppresses EPHA2 expression without affecting
expression of pluripotency factors NANOG and SOX2 (Supple-
mentary Fig. 5D). These data confirm that EPHA2 loss following
OCT4 knockdown is not explained by altered mESC identity.
siRNA knockdown of OCT4 also suppresses Epha2 mRNA levels
(Fig. 5b), consistent with a role for OCT4 in directly regulating
Epha2 gene transcription. Consistent with this, Epha2 gene
regulatory elements form a hub for recruitment for OCT4 and
other pluripotency transcription factors, suggesting that the
pluripotency gene regulatory network directly controls Epha2
gene transcription in mESCs (Fig. 5c, http://codex.stemcells.cam.
ac.uk). Interestingly, EPHA2 is expressed in a homogeneous
manner characteristic of OCT4 (Supplementary Fig. 5E), rather
than the heterogeneous expression pattern characteristic of other
pluripotency factors such as NANOG and KLF4. Taken together,
our data are consistent with a critical and specific function for
OCT4 in regulating EPHA2 expression, although other pluripo-
tency factors may also play a role.
An OCT4-Epha2 transcriptional module controls EPH sig-
nalling. Our results suggest that OCT4 may be an essential factor
for EPH–EFN signalling in pluripotent mESCs. We investigated
this possibility by testing EFN signalling responses upon
OCT4 siRNA knockdown. Following EFNA1 stimulation, EPHA2
immunoprecipitated from mESCs is robustly activated, as mea-
sured by tyrosine phosphorylation (Fig. 5d). However, mESCs
transfected with OCT4 siRNA display loss of EPHA2 tyrosine
phosphorylation in response to EFNA1 stimulation, consistent
with an overall reduction in EPHA2 expression (Fig. 5d). More
importantly, OCT4 suppression abolishes all EFNA1–B1-induced
EPH receptor tyrosine phosphorylation (Fig. 5e). This signal is
specific to tyrosine-phosphorylated EPHA2, as it is abolished by
EPHA2 gene disruption (Fig. 2f) or treatment with the broad-
spectrum tyrosine kinase inhibitor dasatinib (Fig. 5e). These data
establish a critical function for OCT4 in enabling EPH receptor
activation in pluripotent cells.
EPH–EFN regulation in early embryonic cells. Finally, we
investigated whether the EPH–EFN signalling system is regulated in
a similar manner in the early embryo. Single-cell RNA-sequencing
data from distinct stages of early embryonic development43 suggest
that EPH receptors are not expressed in the pluripotent cells of the
morula (embryonic day 2.5) (Supplementary Fig. 6), and are
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therefore unlikely to drive pluripotency at this early embryonic
stage. However, Epha4 is specifically upregulated in the inner cell
mass (E3.5), whilst Epha2 predominates in the pre-implantation
epiblast (E4.5, Supplementary Fig. 6). This is consistent with the
closely related gene expression profiles of mESCs in LIF/FBS and
E4.5 epiblast44. Therefore, EPH receptor expression is established
concomitant to induction of embryonic pluripotency factors,
including Nanog and Sox243.
Our data suggest that pluripotent and differentiated cells
specifically express EPH receptors and EFN ligands, respectively.
We therefore investigated expression patterns of EPH and EFN
family members during early embryonic lineage specification
using single-cell RNA-sequencing data from mouse45 and
human46. As shown previously, Epha4/EPHA4 is specifically
enriched in the pluripotent inner cell mass of mouse (Fig. 6a) and
human (Fig. 6b) embryos, when compared with the surrounding
lineage-specified TE. In contrast, Efna2, Efna4 and Efnb2 are
specifically enriched in lineage-specified mouse TE (Fig. 6c) and
EFNA1 in human TE compared with pluripotent inner cell mass
(Fig. 6d)47,48. These findings suggest that segregated expression of
EPH receptors and EFN ligands in the early embryo plays a key
role in establishing and maintaining pluripotent and differen-
tiated compartments, respectively, consistent with our findings in
mESCs. In summary, we propose a model for EPH receptor
function and regulation in pluripotent cells, whereby FGF4–
ERK1/2–RSK signalling disables EPH signalling, thereby relieving
ERK1/2 inhibition to facilitate pluripotent exit and differentiation
(Fig. 6e).
Discussion
The molecular mechanisms by which cellular signalling networks
promote differentiation of pluripotent cells into specialised cell
types remain poorly understood. In order to address this in a
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systematic, unbiased way, we examine the global phosphopro-
teomic signature associated with mESCs differentiating in response
to FGF4. Our findings indicate that FGF4 extensively rewires
phosphorylation networks beyond previously known pathways and
targets, suggesting that many hitherto unappreciated phosphor-
ylation events may be key regulators of mESC differentiation.
Our analysis describes a critical function for the FGF4–ERK1/2
pathway in disabling the EPH receptor signalling during mESC
differentiation. We demonstrate functional significance by iden-
tifying a role for EPHA2 in maintaining pluripotency gene
expression, restricting cell commitment and induction of differ-
entiation markers, although the role of EPHA2 in lineage speci-
fication remains to be determined. We also provide evidence that
EPHA2 activation supports pluripotency gene expression by
inhibiting ERK1/228,29. EPHA2 has been shown to recruit protein
tyrosine phosphatases34,49–51, and we show that EPHA2 activa-
tion drives recruitment of the protein tyrosine phosphatase
SHP2/PTPN11. As SHP2 is a key scaffold for ERK1/2 activation,
EPHA2 may sequester SHP2 from key FGF-dependent phos-
photyrosine sites that are required for ERK1/2 signalling. Inter-
estingly, this contrasts with a recently described role of secreted
EPHA7, which disrupts activation of ERK1/2 by EPH–EFN sig-
nalling during somatic cell reprogramming52, highlighting the
paradoxical nature of EPH–EFN signalling in distinct biological
contexts.
FGF4 disrupts EPH receptor signalling via a bimodal
mechanism, focussing on the key EPHA2 receptor tyrosine
kinase, which we show is the critical mediator of EFN signalling
responses in mESCs. FGF4–ERK1/2 activates the RSK kinase to
inhibit EPHA2 activation via S/T phosphorylation of a key reg-
ulatory motif, which integrates signals from several other kina-
ses37. Furthermore, we find that Epha2 is a key target of OCT4
and other components of the pluripotency gene regulatory net-
work in mESCs. As such, FGF4–ERK1/2 signalling downregulates
Epha2 during differentiation by suppressing pluripotency factor
expression. By focussing on EPHA2, this dual-inhibitory system
effectively shuts down mESC responses to EFN ligands during
mESC differentiation. We therefore propose that FGF4–ERK1/2
functionally rewires EPH receptor signalling to promote mESC
differentiation. Interestingly, this inhibitory role for FGF signal-
ling appears to be specific to EPHA2 in mESCs, as FGFR–ERK1/
2 signalling promotes activation of the related EPHB2 receptor in
a different cellular system53.
In summary, we report a function for EPH–EFN signalling in
maintaining pluripotency. We also provide evidence that a similar
mechanism operates in pluripotent cells of the early embryo,
where EPH receptors and EFN ligands are specifically enriched in
pluripotent and lineage-specified cells, respectively. Specifically,
pluripotent inner cell mass cells express EPH receptors, whilst the
surrounding TE cells express EFN ligands, suggesting that
EPH–EFN signalling may safeguard pluripotency in the inner cell
mass via contact with adjacent TE cells. Importantly, TE lineage
specification is also dependent on activation of the ERK1/2
pathway54,55, suggesting that the regulatory mechanism identified
in mESCs also operates in early embryos. Furthermore, EFN
ligand engagement by EPH receptors initiates bidirectional sig-
nalling11 to drive segregation of EPH- and EFN-expressing
populations12. Thus, regulation of EPH–EFN by ERK1/2 signal-
ling may be involved in compartmentalisation of the early embryo.
This integrated system would allow organisation of pluripotent
and lineage-specified cells into the distinct cellular compartments
that are essential for proper embryonic development13.
Methods
Cell culture. CCE mouse mESCs were maintained on gelatin-coated plates in
media containing 100 ng/mL GST-tagged Leukemia Inhibitory Factor (LIF), 10%
Fetal Bovine Serum (FBS; Gibco) and 5% knockout serum replacement (Invitro-
gen). Embryoid bodies (EBs) were formed by aggregation of 1200 cells in 20 µl of
mESC medium without LIF forming hanging drops56. At day 4, EBs were trans-
ferred onto gelatin-coated plates and maintained for a further 2–6 days. WT
mESCs were converted from LIF/FBS to 2i culture conditions (N2B27 with 1 µM
PD0325901 and 1 µM CHIR99021)39, and 2i differentiation performed by culturing
cells in N2B27 media alone. Fgf4−/− mESCs were differentiated in mESC medium
without LIF containing 100 ng/ml FGF4 (Peprotech). Cell cultures used in this
paper were tested for mycoplasma infection.
Growth curves and MTS assay. mESCs were plated in LIF/FBS medium at 5 ×
104 cells/cm2, collected by trypsinisation every day and counted using an auto-
mated counter (Invitrogen). Population-doubling time was calculated between days
1 and 2 (exponential growth) as follows: Doubling time= T ln2/ln (Xe/Xb) where
T= incubation time in any unit, Xb= cell number at the beginning and Xe= cell
number at the end.
MTS assay was performed in parallel in 96-well plates using CellTiter-Glo®
Luminescent Cell Viability Assay as indicated by the manufacturers.
mESC commitment assay. The mESC commitment assay protocol was based on
ref. 27. mESCs were plated in 2i medium on gelatin-coated plates at 2 × 104 cells/cm2.
After 24 h, cells were washed with phosphate-buffered saline (PBS) and cultured in
N2B27 media for 96 h or 2i for 72 h, respectively. In total, 10% of 2i-cultured cells or
N2B27-cultured cells were replated in 2i medium and cultured for a further 72 h.
Cells were then fixed in 4% PFA–PBS and stained with alkaline phosphatase (AP)
detection kit (Sigma-Aldrich) according to the manufacturer’s instructions. Plates
were imaged, AP signal was quantified using Image Lab software (Bio-Rad) and
individual colonies counted using ImageJ software (NIH). mESC commitment was
estimated by plotting AP staining intensity from 2i control, and N2B27-differentiated
cells replated in 2i at an equivalent density (10% of total replated in 2i medium for
3 days). Relative commitment was calculated by quantifying AP staining intensity for
Epha2+/+ and Epha2−/− mESCs following N2B27 differentiation, and replating of
either 10% of cells in 2i for a further 72 h, or signal normalised to Epha2+/+ mESCs
in each case.
Cell lysis and immunoprecipitation. Cells were washed with PBS and lysed in ice-
cold FLAG IP–MS lysis buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM
EDTA, 1% NP-40, 0.5% Na Deoxycholate, 10 mM β-Glycerophosphate, 50 mM
NaF, 10 mM NaPPi, 2 mM Sodium Orthovanadate, 10% Glycerol and complete
protease inhibitor tablets [Roche]). EPHA2 was immunoprecipitated for 2 h with
1.5 µg of anti-EPHA2 antibody and 10 µl of Protein G Agarose. Immunoprecipi-
tates were washed three times with lysis buffer prior to immunoblot analysis.
SDS-PAGE and immunoblotting. Proteins resolved by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) were transferred to polyvinylidene
difluoride (PVDF) membranes at 30 V for 90 min. PVDF membranes were blocked
with 3% skimmed milk, incubated with primary antibody (Supplementary Table 2)
at 4 °C overnight and washed three times in tris-buffered saline with 0.1% (v/v)
Tween-20 (TBST). Membranes were incubated in the appropriate secondary
antibody, washed three times in TBST and processed using Immobilon for
enhanced chemiluminescence detection (Millipore). Immunoblots were imaged
using the Chemidoc gel imaging system (Biorad).
Immunofluorescence. Cells were seeded on gelatin-coated coverslips, and fixed with
PBS 4% PFA [w/v], permeabilised in PBS 0.5% Triton X-100 [v/v] for 5 min at room
temperature, blocked with 3% bovine serum albumin [w/v] in PBS and incubated
with EPHA2 antibody (R&D Systems) at 1:200 in blocking buffer for 2 h at room
temperature. Donkey anti-goat Alexa-488 (Thermo Fisher Scientific) was used as a
secondary antibody at 1:500 in blocking buffer for 1 h. DAPI at 1:10,000 was used for
nuclear staining. Cells were mounted using FluorSave reagent (Millipore), images
acquired by a Zeiss 710 confocal microscope and images processed using ImageJ.
RNA extraction and qRT-PCR. RNA was extracted using the OMEGA total RNA
kit and reverse transcribed using iScript reverse transcriptase (Biorad) according to
the manufacturer’s instructions. qPCR was then performed using SsoFast™ Eva-
Green® Supermix (Bio‐Rad). See Supplementary Table 3 for a list of primers. ΔCt
values using GAPDH as a reference gene were used to analyse relative expression,
and the 2− ΔΔCt (Livak) method used to normalise to control when required.
Phosphoproteomic profiling. Fgf4−/− mESCs were cultured in LIF/FBS, and then
starved for 4 h before stimulation with 100 ng/ml FGF4 (Peprotech). Cells were
lysed, proteins extracted and trypsin digested. Phosphopeptide enrichment was
done using TiO2 microspheres (GL Sciences) followed by TMT labelling (Thermo
Fisher Scientific). Samples were fractionated using basic C18 reverse-phase (bRP)
chromatography and subjected to LC–MS/MS. Acquired LC–MS data were ana-
lysed using Proteome Discoverer software v2.2 (Thermo Fisher Scientific). Iden-
tification of significantly modified peptides after 5 and 20 min of stimulation was
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done using the limma package57 (Bioconductor). See Supplementary methods for
further detail.
Quantitative total cell proteomics. Quantitative total cell proteomics analysis was
conducted as described19. mESCs were cultured in LIF/FBS, lysed, boiled and
sonicated before alkylation with iodoacetamide. Lysates were subjected to the SP3
procedure for protein clean-up before elution digest with LysC and Trypsin. TMT
labelling and peptide clean-up were performed according to the SP3 protocol. TMT
samples were fractionated using offline high-pH reverse-phase chromatography.
Peptides were separated into fractions and analysed by LC–MS. The data were
processed, searched and quantified with the MaxQuant software package, version
1.5.3.30. Proteins and peptides were identified using the UniProt mouse reference
proteome database (SwissProt and Trembl accessed on 24.03.2016), and the con-
taminants database integrated in MaxQuant using the Andromeda search engine.
The false-discovery rate was set to 1% for positive identification of proteins and
peptides with the help of the reversed mouse Uniprot database in a decoy
approach. Copy numbers of EPH/EFN proteins were then calculated. See Sup-
plementary methods procedures for further detail.
EFN interaction proteomics. Recombinant EFNA1 and/or EFNB1 ligands (R&D
systems) were clustered using human Fc IgG (Jackson ImmunoResearch) on ice for
1 h. mESCs cultured under standard conditions were lysed in FLAG IP–MS lysis
buffer; clustered EFN ligands added along with Protein G Agarose and incubated
for 1 h at 4 °C. Beads were collected by centrifugation at 1000g for 3 min, super-
natants removed and beads washed three times in lysis buffer. Samples were
analysed by SDS-PAGE, and gels were either transferred for immunoblotting, or
stained with Coomassie blue, and gel slices in the 70–130-kDa range were excised
and prepared for LC–MS/MS analysis.
Preparation of SDS-PAGE LC–MS/MS samples. Protein samples were resolved
by SDS-PAGE and stained with Coomassie R-250 (Novex). Protein bands for
LC–MS/MS analysis were cut into ~1-mm cubes, and washed successively in water,
50% acetonitrile, 0.1 M NH4HCO3 and 50% acetonitrile/50 mM NH4HCO3. All
washes are 0.5 mL for 10 min per gel band; remove all of the liquid between washes.
Protein gel pieces were incubated in 10 mM DTT/0.1 M NH4HCO3 at 37 °C for
20 min, then proteins were alkylated in 50 mM iodoacetamide, 0.1 M NH4HCO3,
for 20 min at room temperature. Gel pieces were washed in 50 mM NH4HCO3 and
then 50 mM NH4HCO3/50% acetonitrile. Once colourless, gel pieces were shrunk
in 0.3 mL of acetonitrile for 15 min, dried in a Speed-Vac and swelled in 25 mM
triethylammonium bicarbonate containing 5 μg/mL of Trypsin and incubated at
30 °C overnight. An equivalent volume of acetonitrile was added, the supernatant
removed, frozen at −80 °C and dried in a Speed-Vac till dry. Samples were stored
at −80 °C prior to LC–MS/MS analysis.
siRNA knockdown. mESCs were transfected with 50 nM siRNA (Dharmacon)
using RNAiMAX (Life Technologies) according to the manufacturer’s instructions,
and incubated for 48 or 72 h before further analysis.
Epha2 CRISPR/Cas9 gene targeting. Epha2−/− mESCs were generated using
dual-mouse Epha2 single-guide RNAs (sgRNAs) cloned into pKN7 and pX335,
respectively (Addgene; MRC Reagents & Services DU52038, DU52047). Constructs
were transfected into mESCs using Lipofectamine LTX (Life Technologies),
selected using 1 µg/ml puromycin for 24 h and cultured for a further 48 h. mESCs
were then plated at clonal density and isolated after 8–10 days of culture. EPHA2
expression was analysed by immunoblotting, and putative positive clones were
confirmed by PCR cloning and sequencing of the targeted region from genomic
DNA (Supplementary Figure 7).
A CRISPR/Cas9 KI strategy was used to introduce 5-point mutations (S893/A,
S898/A, T899/A, S900/A and S902/A) in the EPHA2 C-terminal region. Epha2
sense and antisense sgRNAs were cloned into pBabeD pU6 and pX335, respectively
(Addgene; MRC Reagents & Services DU60602, DU60605). Donor vectors
containing Epha2 cDNA for exons 16 and 17, either WT or 5A, followed by an
IRES2 and EGFP, were cloned into pMA (Addgene; MRC Reagents & Services
DU60674, DU60744) and transfected in conjunction with the mentioned sgRNA-
expressing vectors using Lipofectamine LTX (Life Technologies). Cells were
selected using 1 µg/ml puromycin for 24 h, and cultured for a further 48 h. Cells
were analysed by FACS, and single EGFP-positive cells plated on 96-well plates.
Clones were screened for EGFP, EPHA2 and EPHA2 pS898 by immunoblotting.
Correct gene targeting was confirmed by genomic PCR and DNA sequencing
(Supplementary Fig. 8).
Generation of stable mESC lines. Stable mESC lines were generated by preparing
Sal1-linearised pCAGGS vectors, of which 20 µg were electroporated into mESCs.
Electroporated mESCs were plated in 10-cm dishes and selected with 1 µg/ml
puromycin for 24 h. Cells either underwent single-cell sorting and expansion, or
were cultured at clonal density. Single-cell clones were isolated after 8–10 days in
culture before further analysis.
Statistics and reproducibility. Graphical data were generated and analysed by
GraphPad PRISM software. Continuous variables were expressed as the mean ±
SEM or mean ± SD as indicated in the figure legends. Statistical analyses were
performed as stated in the figure legends. P values of <0.05 were considered as
statistically significant. Unless otherwise stated, representative experiments were
performed at least three times with similar results. The original unprocessed and
uncropped gels/blots with molecular weight marker information are provided in
Supplementary Fig. 9 and as a Source Data file.
Materials. Many reagents generated for this study are available to request through
the MRC‐PPU reagents website (https://mrcppureagents.dundee.ac.uk/).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Phosphoproteomic profiling data from Fig. 1 have been deposited to the
ProteomeXchange Consortium via the PRIDE partner repository with the dataset
identifier PXD012069. The source data underlying all experimental results (Figs. 1c–f; 2a,
c–h; 3, 4b–d, f–j; 5a, b, d, e; 6a–d and Supplementary Figs. 1a, 2, 3a–d, f–h, 4, 5a–d) are
provided as a Source Data file. The authors declare that all other data supporting the
findings of this study are available within the paper and its Supplementary
information files.
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